Lee County campaign demanding an OxyContin recall

The Lee County campaign demanding an OxyContin recall was a grassroots response to signs of escalating harm in southwestern Virginia. Organized by physician Art Van Zee and the Lee Coalition for Health, it moved from letters to Purdue Pharma to a large public petition drive in early 2001. Its central significance lay in making local evidence—overdoses, injection, disease, and the burdens of reaching treatment—an argument for action on the drug’s marketing, formulation, and availability, rather than treating each consequence as an isolated problem.

Local warnings and the campaign’s formation

Art Van Zee and his wife, lawyer Sue Ella Kobak, recognized that communities in the region were confronting a shared problem and needed to organize. Within weeks, Art Van Zee had helped convene public meetings under the Lee Coalition for Health, a grassroots group of ministers, social workers, and other community members. With Sue Ella Kobak’s editing and coaching, he began writing to Purdue Pharma about patterns he was seeing among patients, including injection, frequent overdoses, and increased hepatitis C.

In his first letter to Purdue Pharma medical director David Haddox, dated August 20, 2000, Art Van Zee urged the company to investigate its prescribing patterns in the region and emphasized the breadth of the problem. In a subsequent letter, he warned that affected communities might be early indicators of a much wider crisis, comparing their role to that of San Francisco and New York during the early years of HIV. Purdue Pharma’s initial reply was a set of Adverse Event Report Forms. To Van Zee, that response did not match the scale of the warning he was trying to convey.

The coalition’s appeal was grounded in both local observation and clinical context. At a forum for area doctors and families, Van Zee brought in Yale University substance-abuse experts to explain the physical and psychological pressures of opioid withdrawal. They also described addiction as a chronic illness that commonly involves relapse: figures cited in the book indicate that 40 to 60 percent of people addicted to opioids can achieve remission with medication-assisted treatment, but sustained remission may take ten years or longer, while approximately 4 percent die of overdose each year. The forum presented the region’s experience not as a brief episode of misconduct but as a continuing public-health crisis requiring sustained care.

Competing accounts of pain and abuse

The forum also exposed the dispute at the center of the campaign. When researchers recommended that physicians treating severe pain consider drugs less prone to abuse, a Purdue Pharma representative who had attended without identifying himself challenged the recommendation. He argued that inadequate pain treatment, rather than OxyContin’s misuse, was the problem. That confrontation sharpened the divide between Van Zee and the company, and between him and many fellow physicians who had embraced the pain-management movement’s argument that pain was widely undertreated.

Van Zee did not frame his position as a demand to ignore pain. He asked Purdue Pharma to stop aggressively marketing OxyContin for noncancer pain and to reformulate it so that it would be less susceptible to abuse. To show that a different design was possible, he pointed to the makers of Talwin: in 1982 they had added naloxone, a narcotic antagonist, to the painkiller, and diversion and misuse fell immediately. The example gave his request a practical dimension. The campaign was not only calling attention to harm; it was asking the manufacturer to change the conditions that could enable misuse.

The warnings were set against developments across the region. In Tazewell County, Virginia, a newspaper reported that 150 people had been charged with OxyContin-related felonies between August 1999 and August 2000. In a county of 44,000, ten drugstore armed robberies had occurred over the preceding eighteen months. Some cases involved unemployed miners whose OxyContin use followed serious injuries and surgery; the reported crimes included stealing copper for resale to fund purchases. These figures and accounts gave urgency to the coalition’s contention that the consequences were visible in ordinary community life, not confined to a narrow circle of patients.

Petition drive and public mobilization

In early 2001, Art Van Zee and the Lee Coalition for Health launched an online petition asking the U.S. Food and Drug Administration to order a recall of OxyContin. The website, recalloxycontinnow.org, carried the campaign beyond the physician’s correspondence with the company and turned the demand into a public action that residents could join. It also marked a sharper break with the pharmaceutical industry and with many of Van Zee’s medical peers, who did not share his call for a recall.

The petition received more than ten thousand signatures, most of them from Lee County, Virginia. A standing-room-only town hall at the local high school in March 2001 helped produce the response. Eight hundred people attended, with some sitting in the auditorium aisles. The size of the gathering was striking in a place where, as one organizer observed, many residents had little money for gasoline. The meeting made the campaign’s local reach tangible: the petition was not simply a professional dispute over prescribing but a collective appeal by families and residents confronted by the drug’s effects.

The public argument was also reflected in law-enforcement assessments of the crisis. Roanoke-based U.S. attorney Bob Crouch compared OxyContin’s impact to crack in southwestern Virginia, as overdose deaths attributed to OxyContin substantially exceeded those caused by cocaine and heroin. The comparison placed the petition within an escalating regional emergency, even as the campaign’s principal demand remained directed to the federal regulator: order a recall.

Responses and limits

The month after the town hall, the Drug Enforcement Administration developed a national action plan to monitor Purdue Pharma. It asked the company to limit distribution, reconsider its marketing strategy, and consider a formulation resistant to abuse. The plan was unprecedented in the agency’s history: for the first time, it targeted a specific drug and sought to have its manufacturer help police diversion and misuse. Its overlap with the coalition’s concerns demonstrated that Van Zee’s local warnings had become part of a broader national debate, though the evidence does not establish that the petition alone produced the federal action.

Purdue Pharma answered with a ten-point plan that included tamper-resistant prescription pads, an educational program warning teenagers about prescription-drug dangers, and a $100,000 grant to create a statewide prescription monitoring program intended to deter doctor-shopping. The company also stopped distributing its 160-milligram OxyContin pill and reduced shipments to Mexico after reports that the drug was being smuggled back into the United States. These steps addressed distribution and misuse, but they were distinct from the requested FDA recall and did not constitute acceptance of Van Zee’s full program of demands.

The campaign therefore stands as both an organized local challenge and a record of the limits of early warnings. Van Zee and the Lee Coalition for Health assembled clinical testimony, concrete community evidence, and a mass petition to argue that OxyContin’s harms called for action beyond individual prescribing decisions. The federal and corporate measures that followed addressed some of the same risks, while leaving the central recall demand unresolved in this account. The campaign’s lasting force is its insistence that the people living with the consequences had evidence worth hearing—and that a manufacturer’s response to such evidence was itself part of the public-health question.